Skip to main content

Table 2 Combinations of immunological checkpoint inhibitors in US clinical trials

From: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Immunological checkpoint inhibitorCombined drugApplicationNumber of volunteersOS (months)Rate of OS
(at 6 months)
ORR (%)DOR (months)PFS (months)
pembrolizumabEpacadostat [168]Unresectable or metastatic melanoma35484.134.24.70
Pomalidomide+Dexamethasone [169]Refractory or relapsed and refractory multiple myeloma12621.0 (14.2-NA)5.7
nivolumabIpilimumab [170, 171]Previously untreated advanced melanoma3130.8657.611.50
Previously untreated advanced or metastatic renal cell carcinoma55038.712.42
ipilimumabSargramostim [172]stage III or stage IV melanoma untreatable by surgery12317.5 (14.9-NA)3.10
Dacarbazine [173]untreated unresectable stage III or IV melanoma25011.1719.32.76
Paclitaxel/
Carboplatin [174]
Lung cancer—non small cell squamous38813.375.55
Nab-Paclitaxel + Carboplatin [175]Non-squamous non-Small cell lung cancer48318.67.00
atezolizumabCarboplatin + Etoposide [176]Untreated extensive-stage small cell lung cancer20112.35.2
Cobimetinib [177]Metastatic colorectal adenocarcinoma1838.871.971.91
Bevacizumab [178]Renal cell carcinoma1788.90